AU2016362597C1 - Vaccination with MICA/B alpha 3 domain for the treatment of cancer - Google Patents

Vaccination with MICA/B alpha 3 domain for the treatment of cancer Download PDF

Info

Publication number
AU2016362597C1
AU2016362597C1 AU2016362597A AU2016362597A AU2016362597C1 AU 2016362597 C1 AU2016362597 C1 AU 2016362597C1 AU 2016362597 A AU2016362597 A AU 2016362597A AU 2016362597 A AU2016362597 A AU 2016362597A AU 2016362597 C1 AU2016362597 C1 AU 2016362597C1
Authority
AU
Australia
Prior art keywords
protein
mica
ser
leu
ferritin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016362597A
Other languages
English (en)
Other versions
AU2016362597A1 (en
AU2016362597B2 (en
Inventor
Soumya BADRINATH
Kai Wucherpfennig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2016362597A1 publication Critical patent/AU2016362597A1/en
Publication of AU2016362597B2 publication Critical patent/AU2016362597B2/en
Priority to AU2022201940A priority Critical patent/AU2022201940B2/en
Application granted granted Critical
Publication of AU2016362597C1 publication Critical patent/AU2016362597C1/en
Priority to AU2025213685A priority patent/AU2025213685A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016362597A 2015-12-04 2016-12-05 Vaccination with MICA/B alpha 3 domain for the treatment of cancer Active AU2016362597C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022201940A AU2022201940B2 (en) 2015-12-04 2022-03-21 Vaccination with MICA/B alpha 3 domain for the treatment of cancer
AU2025213685A AU2025213685A1 (en) 2015-12-04 2025-08-08 Vaccination with MICA/B alpha 3 domain for the treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US62/263,377 2015-12-04
US201662422454P 2016-11-15 2016-11-15
US62/422,454 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201940A Division AU2022201940B2 (en) 2015-12-04 2022-03-21 Vaccination with MICA/B alpha 3 domain for the treatment of cancer

Publications (3)

Publication Number Publication Date
AU2016362597A1 AU2016362597A1 (en) 2018-06-07
AU2016362597B2 AU2016362597B2 (en) 2022-02-17
AU2016362597C1 true AU2016362597C1 (en) 2022-05-26

Family

ID=57590885

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016362597A Active AU2016362597C1 (en) 2015-12-04 2016-12-05 Vaccination with MICA/B alpha 3 domain for the treatment of cancer
AU2022201940A Active AU2022201940B2 (en) 2015-12-04 2022-03-21 Vaccination with MICA/B alpha 3 domain for the treatment of cancer
AU2025213685A Pending AU2025213685A1 (en) 2015-12-04 2025-08-08 Vaccination with MICA/B alpha 3 domain for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022201940A Active AU2022201940B2 (en) 2015-12-04 2022-03-21 Vaccination with MICA/B alpha 3 domain for the treatment of cancer
AU2025213685A Pending AU2025213685A1 (en) 2015-12-04 2025-08-08 Vaccination with MICA/B alpha 3 domain for the treatment of cancer

Country Status (24)

Country Link
US (3) US10993971B2 (OSRAM)
EP (1) EP3383426A1 (OSRAM)
JP (3) JP7099956B2 (OSRAM)
KR (1) KR20180088458A (OSRAM)
CN (1) CN108770343A (OSRAM)
AU (3) AU2016362597C1 (OSRAM)
BR (1) BR112018010705A8 (OSRAM)
CA (1) CA3005910A1 (OSRAM)
CL (3) CL2018001470A1 (OSRAM)
CO (1) CO2018006642A2 (OSRAM)
CR (2) CR20180350A (OSRAM)
CU (2) CU20210061A7 (OSRAM)
EA (1) EA201891287A1 (OSRAM)
IL (1) IL259490A (OSRAM)
MX (2) MX2018006785A (OSRAM)
MY (1) MY199248A (OSRAM)
NZ (1) NZ742663A (OSRAM)
PE (2) PE20230495A1 (OSRAM)
PH (1) PH12018501170A1 (OSRAM)
RU (2) RU2747296C2 (OSRAM)
SG (1) SG11201804597TA (OSRAM)
TN (1) TN2018000187A1 (OSRAM)
WO (1) WO2017096374A1 (OSRAM)
ZA (1) ZA202204223B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519596A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
WO2019195276A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
MX2020010199A (es) 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094849A2 (en) * 2002-05-10 2003-11-20 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
US20090104170A1 (en) 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US8889044B2 (en) 2009-12-18 2014-11-18 Kao Corporation Method for producing mesoporous silica particles
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
BR112014006887A2 (pt) * 2011-09-23 2017-04-04 Univ Oslo corpos de vacina direcionados às células dendríticas de apresentação cruzada
EP3210625B1 (en) 2011-09-30 2019-08-28 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
RU2656183C2 (ru) * 2012-02-07 2018-05-31 Иннейт Фарма Связывающие mica агенты
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
BR112015021576A2 (pt) 2013-03-15 2017-10-10 Dana Farber Cancer Inst Inc peptídeos terapêuticos
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094849A2 (en) * 2002-05-10 2003-11-20 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Also Published As

Publication number Publication date
MX2022010194A (es) 2022-09-19
PE20181158A1 (es) 2018-07-19
IL259490A (en) 2018-07-31
JP2024177207A (ja) 2024-12-19
EA201891287A1 (ru) 2018-11-30
JP7099956B2 (ja) 2022-07-12
JP2018536002A (ja) 2018-12-06
AU2016362597A1 (en) 2018-06-07
CU20180050A7 (es) 2018-11-06
AU2022201940A1 (en) 2022-04-14
CL2021001256A1 (es) 2021-12-31
US20250064863A1 (en) 2025-02-27
PH12018501170A1 (en) 2019-01-21
JP7564842B2 (ja) 2024-10-09
US10993971B2 (en) 2021-05-04
ZA202204223B (en) 2023-12-20
RU2747296C2 (ru) 2021-05-04
US20210299186A1 (en) 2021-09-30
TN2018000187A1 (en) 2019-10-04
CN108770343A (zh) 2018-11-06
CU24609B1 (es) 2022-06-06
PE20230495A1 (es) 2023-03-23
BR112018010705A2 (pt) 2018-11-21
MY199248A (en) 2023-10-23
KR20180088458A (ko) 2018-08-03
AU2016362597B2 (en) 2022-02-17
AU2025213685A1 (en) 2025-08-28
JP2022130623A (ja) 2022-09-06
CL2018001470A1 (es) 2018-12-21
SG11201804597TA (en) 2018-06-28
CR20180350A (es) 2018-10-02
MX2018006785A (es) 2018-11-09
RU2021109510A (ru) 2021-04-16
WO2017096374A1 (en) 2017-06-08
NZ742663A (en) 2023-02-24
AU2022201940B2 (en) 2025-05-08
BR112018010705A8 (pt) 2019-02-26
CL2023003217A1 (es) 2024-06-28
US20180353581A1 (en) 2018-12-13
CR20230116A (es) 2023-05-05
CU20210061A7 (es) 2022-02-04
CA3005910A1 (en) 2017-06-08
RU2018123307A (ru) 2020-01-13
EP3383426A1 (en) 2018-10-10
CO2018006642A2 (es) 2018-07-10
RU2018123307A3 (OSRAM) 2020-04-20

Similar Documents

Publication Publication Date Title
AU2022201940B2 (en) Vaccination with MICA/B alpha 3 domain for the treatment of cancer
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
JP2008523818A (ja) 腫瘍免疫療法におけるフラジェリンの使用
CA2912736C (en) Gastrin peptide immunogenic composition
CA2551442A1 (en) Nematode polypeptide adjuvant
Nathalie et al. Therapeutic MUC1-based cancer vaccine expressed in flagella-efficacy in an aggressive model of breast cancer
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
NZ506637A (en) Tumor associated antigen 791tgp72
EA041345B1 (ru) Вакцинация с использованием альфа3-домена mica/b для лечения рака
WO2024222886A1 (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
TW202544252A (zh) 經修飾的CMV類病毒粒子及貓IL-1β突變蛋白抗原之獸醫組成物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 FEB 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 02 FEB 2022

FGA Letters patent sealed or granted (standard patent)